Abstract 578P
Background
This study aimed to describe efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for elderly patients (≥65 years) with treatment-naïve EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Methods
Patients with treatment-naïve EGFR-mutated advanced NSCLC were enrolled at several hospitals in Taiwan between May 2014 and January 2018. Patient characteristics, including age, sex, performance status (PS), smoking history, tumor morphology, mutation type, stage, metastasis, efficacy and safety of EGFR-TKIs were compared. Univariate and multivariate analyses were performed to explore possible prognostic factors.
Results
This study enrolled 1,343 patients with treatment-naïve EGFR-mutated advanced NSCLC, of which 554 were aged <65 years, 383 were aged 65–74 years, 323 were aged 75–84 years, and 83 were aged ≥85 years. In elderly patients, afatinib showed significantly better efficacy, with a median progression-free survival (PFS) of 14.7 months and overall survival (OS) of 22.2 months, than gefitinib (9.9 months and 17.7 months, respectively) and erlotinib (10.8 months and 18.5 months, respectively; PFS: p=0.003; OS: p=0.026). However, patients treated with afatinib also experienced more grade ≥3 adverse events than those treated with gefitinib and erlotinib, including skin toxicities (6.1% vs. 1.8% vs. 3.9%, p=0.052), paronychia (5.1% vs. 0.5% vs. 2.3%, p=0.006), mucositis (1.9% vs. 0% vs. 1.1%, p=0.122), and diarrhea (9.3% vs. 2.3% vs. 1.5%, p<0.0001). PS of 2-4, stage IV disease, liver, bone, pleura, adrenal, and pericardial metastases, and EGFR-TKI treatment with gefitinib were associated with poor PFS, while age of ≥ 85 years, PS of 2-4, stage IV disease, liver, brain, bone, pleura, adrenal, and pericardial metastases, and EGFR-TKI treatment with gefitinib were associated with poor OS. These factors were independent prognostic factors for both PFS and OS.
Conclusions
For elderly patients with EGFR-mutated advanced NSCLC, afatinib was associated with better efficacy than gefitinib or erlotinib in elderly patients with EGFR-mutated advanced NSCLC as a first-line treatment with acceptable AEs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract